Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made. At the European Association for the Study of Diabetes’ 58th annual meeting this week, promising data was presented from Novo Nordisk’s phase 3a ONWARDS 2 trial – a trial comparing a potential once-weekly basal insulin, with a well-known once-daily basal insulin in people with type 2 diabetes.
In today’s pharmaphorum podcast, Florian Baeres, Corporate Vice President for global medical affairs at Novo Nordisk, joins editor in chief Jonah Comstock to talk about the innovative once-weekly insulin currently in development and how it could change the game for people currently managing their type 2 diabetes with daily injections.
They discuss the status quo for people with type 2 diabetes, the nature and status of the ONWARDS phase 3a clinical trial programme, and what the future might hold as this new treatment proceeds through development. Tune in below for a fascinating discussion of the cutting edge of diabetes management.
You can listen to episode 60 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on iTunes, Spotify, acast, Stitcher and Podbean.
This post was originally published on Source Link